Determination of differences in the specificity and negative predictive value for PSMA PET compared to MRI is limited in this trial as all patients were diagnosed with prostate cancer before imaging (ie, the theoretical number of true negative patients is zero). This evidence concerns the gene FOLH1 and prostate carcinoma.